Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Guggenheim Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by equities research analysts at Guggenheim from $815.00 to $865.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price suggests a potential upside of 32.25% from the stock’s previous close.

REGN has been the subject of a number of other research reports. Sanford C. Bernstein upped their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Citigroup increased their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a report on Monday, October 13th. UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Finally, Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $813.78.

Regeneron Pharmaceuticals Stock Up 0.2%

Regeneron Pharmaceuticals stock opened at $654.04 on Wednesday. The business has a fifty day moving average of $580.56 and a two-hundred day moving average of $564.66. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The firm has a market cap of $69.32 billion, a P/E ratio of 15.66, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $883.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the business earned $12.46 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after acquiring an additional 121,545 shares during the last quarter. State Street Corp grew its position in Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock worth $2,536,801,000 after purchasing an additional 42,343 shares during the period. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Franklin Resources Inc. grew its position in Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock worth $1,214,585,000 after purchasing an additional 36,821 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after purchasing an additional 89,579 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.